Navigation Links
FDA Advisers Call for Revised Labels for Osteoporosis Drugs
Date:9/9/2011

s, said length of treatment should be considered on an individual basis. His study suggested patients at mild risk might discontinue drug treatment after five years for as long as no fractures occurred and no bone loss was evident. Higher-risk patients could take the drugs for 10 years and perhaps then take a "holiday" from bisphosphonates of one or two years.

"It would probably be helpful if FDA or some official organization could provide guidelines on duration of treatment, details of drug holidays, etc., but there is probably not enough information in the literature for recommendations based on science," Watts said before Friday's vote.

Common bisphosphonates are taken in tablet form or by injection. They include: Fosamax (alendronate sodium) made by Merck & Co., Inc.; Actonel and Atelvia (risedronate sodium) made by Warner Chilcott; Boniva (ibandronate sodium) from Roche Therapeutics, Inc.; and Reclast (zoledronic acid) from Novartis Pharmaceuticals Corp.

More information

For more information on osteoporosis, visit the U.S. National Library of Medicine.

SOURCES: Elizabeth Shane, M.D., past president, American Society for Bone and Mineral Research, endocrinologist and professor of medicine, Columbia University, New York City; Nelson B. Watts, M.D., director, University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, Ohio; Associated Press; Bloomberg News


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. FDA Advisers Urge Infant Doses for Kids OTC Fever Relievers
2. FDA Advisers Renew Review on Whether to Ban Menthol Cigarettes
3. FDA Advisers Endorse New Lupus Drug
4. FDA Advisers Consider New Lupus Drug
5. FDA Advisers Back Anemia Drugs for Kidney Patients
6. FDA Advisers Consider Approval of Genetically Modified Salmon
7. FDA Advisers Weigh Approval of Genetically Modified Salmon
8. FDA Advisers Divided on Whether to Ban Diet Drug Meridia
9. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
10. FDA to Broaden Disclosure on Advisers Conflicts of Interest
11. FDA Advisers Urge Stricter Regulation of Tanning Beds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Advisers Call for Revised Labels for Osteoporosis Drugs
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Feb. 8 Aton Pharma, Inc., a diversified ... has joined the company as Vice President, Commercial Operations ... A. Fishbein assumes the same role for the Ophthalmic ... LLC, Aton is focused on the development and commercialization of ...
... , , , , , ... , Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink ... of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today,that ... the fiscal year ended, October 31, 2009 on time. ...
... ... Corporation (Pinksheets: NUEC) (“NuEarth”), a manufacturer and marketer of "Clean ... Laboratory and Research Division “TerraSolv SA” has received final approval ... additional $1.3 Million laboratory service contract with the Nigerian National ...
... in the gut, triggering bone formation , MONDAY, Feb. 8 ... the gut cured osteoporosis in lab mice and rats, a ... serotonin in the gut hinders bone formation. Most current drugs ... build bone. , "New therapies that inhibit the production of ...
... divide abnormally, researchers say , MONDAY, Feb. 8 (HealthDay News) ... week may have double the risk of developing deadly pancreatic ... But the overall number of people developing the malignancy remains ... new cases last year. , "Soft drinks are linked with ...
... , WOONSOCKET, ... CVS ) today announced record revenues, operating profit, and ... ended December 31, 2009 . , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) ... of 2009, increased $1.7 billion to $25.8 billion , up ...
Cached Medicine News:Health News:Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 3Health News:NuEarth Signs $1.3 Million Laboratory Contract 2Health News:NuEarth Signs $1.3 Million Laboratory Contract 3Health News:Drug Cures Osteoporosis in Mice 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 3Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 2Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 3Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 5Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 6Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 7Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 8Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 9Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 10Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 11Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 12Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 13Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 14Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 15Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 16Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 17Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 18Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 19Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 20Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 21Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 22Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 23Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 24Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 25Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 26
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)... -- A novel wearable injector slightly larger than an Oreo ... patients to self-inject prescription drugs in the large doses ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   ... of injector that does not exist today for self-administration ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 20 Thomson Reuters, a global provider ... the newest version of its award-winning Clinical ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: ... hospital-based clinicians to access complete patient clinical ...
... VPHM ) third quarter financial results for 2010 ... before the open of the U.S. financial markets. ... webcast at 9:00 a.m. Eastern Time on the same day. ... third quarter financial results and other business. ...
Cached Medicine Technology:Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: